Catalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for MR-141 (phentolamine ophthalmic solution 0.75%) in Presbyopia. The expected timing is based on the latest available company guidance and may change.
VEGA-3 Trial. 6/26/25- Announced positive top-line results. Targeting application to FDA in H2 2025. 02/25/26:- sNDA accepted for MR-141 in presbyopia; PDUFA decision October 17, 2026; VEGA-3 data at ASCRS/ARVO 2026. 02/26/26:- sNDA and October 17, 2026 PDUFA date reiterated in 2025 results. 04/10/26:- Full VEGA-3 Ph3 results presented at ASCRS Apr 11, 2026. PDUFA Oct 17, 2026. 05/07/26:- Q1 2026 update reiterates VEGA-3 full results at ASCRS April 2026; PDUFA Oct 17, 2026. 08/06/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.